文献速递肿瘤 PET/CT

18F-FDG-PET/CT用于新诊断ER阳性和HER2阳性乳腺癌患者的全身分期

18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-29

本研究回顾性评估18F-FDG-PET/CT在新诊断ER+/HER2-和HER2+乳腺癌患者中检出未疑及远处转移的价值。238例ER+/HER2-和245例HER2+患者中,IIB期总体升级率为14%(95%CI:9-20%),与既往三阴性乳腺癌IIB期升级率15%(95%CI:9-24%)相似。作者认为NCCN指南应考虑将IIB期乳腺癌患者纳入初诊时18F-FDG-PET/CT全身分期。

要点

  • ER+/HER2-乳腺癌患者中,PET/CT检出未疑及远处转移:IIA期3/71(4%)、IIB期13/95(14%)、III期15/57(26%)。
  • HER2+乳腺癌患者中,PET/CT检出未疑及远处转移:IIA期3/72(4%)、IIB期13/93(14%)、III期13/59(22%)。
  • IIB期总体升级率为14%(95%CI:9-20%),与既往三阴性乳腺癌IIB期升级率15%(95%CI:9-24%)相似。

核心结论

  • 18F-FDG-PET/CT在14%(95%CI:9-20%)的IIB期ER+/HER2-和HER2+乳腺癌患者中检出远处转移,与既往三阴性乳腺癌IIB期升级率15%(95%CI:9-24%)相似。
  • 这些患者中检出未疑及远处转移改变了治疗和预后。
  • 作者认为NCCN指南应考虑将IIB期乳腺癌患者纳入初诊时18F-FDG-PET/CT全身分期。

研究设计与样本

  • 经机构审查委员会批准的回顾性研究,通过医疗信息系统筛选在全身或放疗前接受18F-FDG-PET/CT的ER+/HER2-和HER2+乳腺癌患者。
  • 初始分期由乳腺X线摄影、超声、磁共振成像和/或手术确定。
  • 共评估238例ER+/HER2-和245例HER2+符合纳入标准的患者。

主要发现

  • ER+/HER2-乳腺癌患者中,18F-FDG-PET/CT检出未疑及远处转移:初始IIA期3/71(4%)、IIB期13/95(14%)、III期15/57(26%)。
  • HER2+乳腺癌患者中,18F-FDG-PET/CT检出未疑及远处转移:初始IIA期3/72(4%)、IIB期13/93(14%)、III期13/59(22%)。
  • IIB期总体升级率为14%(95%CI:9-20%)。

关键数值与推荐

  • ER+/HER2-乳腺癌患者中,18F-FDG-PET/CT检出未疑及远处转移:IIA期3/71(4%)、IIB期13/95(14%)、III期15/57(26%)。
  • HER2+乳腺癌患者中,18F-FDG-PET/CT检出未疑及远处转移:IIA期3/72(4%)、IIB期13/93(14%)、III期13/59(22%)。
  • IIB期总体升级率为14%(95%CI:9-20%)。
  • 既往三阴性乳腺癌IIB期升级率为15%(95%CI:9-24%)。

临床怎么用

  • 作者认为NCCN指南应考虑将IIB期乳腺癌患者纳入初诊时18F-FDG-PET/CT全身分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study assesses 18F-FDG-PET/CT for patients with newly diagnosed estrogen receptor-positive/human epidermal growth factor receptor-negative (ER+/HER2-) and human epidermal growth factor receptor-positive (HER2+) breast cancer. METHODS: In this Institutional Review Board-approved retrospective study, our Healthcare Information System was screened for patients with ER+/HER2- and HER2+ breast cancer who underwent 18F-FDG-PET/CT prior to systemic or radiation therapy. The initial stage was determined from mammography, ultrasound, magnetic resonance imaging, and/or surgery.18F-FDG-PET/CT was evaluated to identify unsuspected extra-axillary regional nodal and distant metastases. The proportion of patients upstaged overall and stratified by stage and receptor phenotypes was calculated along with confidence intervals (CI). RESULTS: A total of 238 patients with ER+/HER2- and 245 patients with HER2+ who met inclusion criteria were evaluated. For patients with ER+/HER2-breast cancer, 18F-FDG-PET/CT revealed unsuspected distant metastases in 3/71 (4%) initial stage IIA, 13/95 (14%) stage IIB, and 15/57 (26%) stage III. For patients with HER2+ breast cancer, 18F-FDG-PET/CT revealed unsuspected distant metastases in 3/72 (4%) initial stage IIA, 13/93 (14%) stage IIB, and 13/59 (22%) stage III. The overall upstaging rate for IIB was 14% (95% confidence interval (CI): 9-20%). CONCLUSIONS: 18F-FDG-PET/CT revealed distant metastases in 14% (95% CI: 9-20%) of patients with stage IIB ER+/HER2- and HER2+ breast cancer, which is similar to upstaging rates previously seen in patients with stage IIB triple-negative breast cancer (15%, 95% CI: 9-24%). The detection of unsuspected distant metastases in these patients alters treatment and prognosis. NCCN guidelines should consider adding patients with stage IIB breast cancer for consideration of systemic staging with 18F-FDG-PET/CT at the time of initial diagnosis.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ulaner GA, Castillo R, Wills J, et al. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28456837. doi:10.1007/s00259-017-3709-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。